Zevra Therapeutics (NASDAQ:ZVRA) Earns Buy Rating from HC Wainwright

Zevra Therapeutics (NASDAQ:ZVRA)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They currently have a $20.00 price objective on the stock. HC Wainwright’s price target would indicate a potential upside of 152.53% from the stock’s current price.

A number of other equities analysts have also commented on the company. Guggenheim set a $21.00 price objective on Zevra Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, February 4th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $25.00 price objective on shares of Zevra Therapeutics in a research report on Wednesday. Canaccord Genuity Group dropped their target price on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research report on Thursday, November 14th. Finally, Citigroup reiterated an “outperform” rating on shares of Zevra Therapeutics in a research report on Wednesday. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $21.71.

Zevra Therapeutics Stock Down 1.9 %

Shares of ZVRA stock opened at $7.92 on Thursday. The firm has a market capitalization of $422.74 million, a P/E ratio of -4.02 and a beta of 1.98. The firm’s fifty day moving average price is $7.95 and its two-hundred day moving average price is $8.14. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84. Zevra Therapeutics has a 1 year low of $4.20 and a 1 year high of $9.76.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings results on Tuesday, March 11th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.28). The business had revenue of $12.00 million during the quarter, compared to the consensus estimate of $8.93 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. On average, equities analysts predict that Zevra Therapeutics will post -1.95 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO R. Laduane Clifton sold 11,000 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $86,460.00. Following the sale, the chief financial officer now directly owns 51,361 shares in the company, valued at approximately $403,697.46. This represents a 17.64 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Neil F. Mcfarlane sold 61,273 shares of the company’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $7.86, for a total value of $481,605.78. Following the sale, the chief executive officer now owns 222,060 shares in the company, valued at approximately $1,745,391.60. This represents a 21.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 85,773 shares of company stock valued at $674,176. 2.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Zevra Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets purchased a new stake in Zevra Therapeutics in the fourth quarter valued at approximately $53,000. XTX Topco Ltd purchased a new position in shares of Zevra Therapeutics in the third quarter valued at about $94,000. China Universal Asset Management Co. Ltd. purchased a new stake in Zevra Therapeutics in the 4th quarter worth approximately $94,000. Intech Investment Management LLC purchased a new position in Zevra Therapeutics during the 3rd quarter valued at $95,000. Finally, Virtu Financial LLC bought a new position in shares of Zevra Therapeutics in the 3rd quarter worth approximately $127,000. Hedge funds and other institutional investors own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.